Litigation Details for Biogen Inc. v. Teva Pharmaceuticals Development Inc. (D. Del. 2021)

Biogen Inc. v. Teva Pharmaceuticals Development Inc. (D. Del. 2021)

Docket		Date Filed	2021-03-17
Court	District Court, D. Delaware	Date Terminated	2021-10-08
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS DEVELOPMENT INC.
Patents	10,080,733; 8,669,281; 9,090,558
Attorneys	Karen Elizabeth Keller
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Biogen Inc. v. Teva Pharmaceuticals Development Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-03-17				External link to document
2021-03-17	1	Complaint	U.S. Patent Nos. 8,669,281 (“the ’281 patent”); 9,090,558 (“the ’558 patent”); and 10,080,733 (“the … 1. This is an action for patent infringement under the patent laws of the United States, Title…the ’733 patent”) (collectively “the Asserted Patents”). Teva notified Plaintiffs that it had submitted…Asserted Patents in the event that Teva’s ANDA Product is approved before the Asserted Patents expire.…assignee of the ’281 patent. 19. BSM is the exclusive licensee of the ’281 patent. 20.	External link to document
2021-03-17	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,669,281 ;9,090,558 ;10,080,733. (mal) …2021 8 October 2021 1:21-cv-00389 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Biogen Inc. v. Teva Pharmaceuticals Development Inc. Litigation Summary and Patent Analysis

Last updated: August 8, 2026

Biogen’s action against Teva concerned an ANDA for generic dimethyl fumarate delayed-release capsules, the generic equivalent of Tecfidera. The case centered on U.S. Patent No. 8,399,514, which claimed a 480 mg-per-day dimethyl fumarate dosing regimen for multiple sclerosis. A Delaware jury initially found infringement and validity and awarded Biogen approximately $176.5 million. The district court later entered judgment for Teva after applying the invalidity determination from earlier litigation involving the same patent. The case illustrates the limits of relying on dosage-regimen patents after a related patent has been held invalid for lack of written description.

What was Biogen v. Teva Pharmaceuticals Development about?

Biogen filed the action in the U.S. District Court for the District of Delaware on March 26, 2021, after receiving Teva’s Paragraph IV certification concerning an ANDA for dimethyl fumarate delayed-release capsules. The case number was 1:21-cv-00389.

The asserted patent was:

Patent	Subject matter	Listed expiration	Drug product
U.S. Patent No. 8,399,514	480 mg/day dimethyl fumarate regimen for treating multiple sclerosis	June 1, 2028	Tecfidera

Biogen alleged that Teva’s proposed generic product would infringe claims covering administration of 480 mg of dimethyl fumarate per day. Teva denied infringement and challenged the patent’s validity, principally on written-description and enablement grounds.

Tecfidera contains dimethyl fumarate and was approved by the FDA in 2013 for relapsing forms of multiple sclerosis. The commercial value of the patent dispute was substantial because Tecfidera was one of Biogen’s largest products and the asserted patent had a listed expiration date well after the 2021 filing.

What patent did Biogen assert against Teva?

Biogen asserted U.S. Patent No. 8,399,514, titled "Methods of treating multiple sclerosis." The patent claims treatment using a total daily dose of 480 mg of dimethyl fumarate, generally administered as two 240 mg doses.

The central patent issue was whether the specification adequately described and supported the claimed 480 mg daily dose. The earlier litigation involving Mylan had already produced a Federal Circuit decision holding the patent invalid for lack of written description. That decision materially affected the Teva case.

The patent estate around Tecfidera included dosage, formulation, and manufacturing rights, but the Teva case focused on the '514 patent and the claimed therapeutic regimen. The litigation did not primarily concern a chemical composition patent covering dimethyl fumarate itself.

What did the '514 patent claim?

The asserted claims generally covered:

• Treatment of multiple sclerosis;
• Administration of dimethyl fumarate;
• A total daily dose of 480 mg;
• Use of delayed-release dosage forms in the commercial product context.

The patent’s commercial significance came from the relationship between the claimed dose and the FDA-approved Tecfidera regimen. A generic product designed to match the approved 240 mg capsule strength and twice-daily administration could fall within the asserted claims.

What was the litigation timeline?

Date	Event
2013	FDA approved Tecfidera for multiple sclerosis
June 1, 2007	Earliest relevant filing date for the '514 patent family
2020	Federal Circuit affirmed invalidity of the '514 patent in Biogen v. Mylan
March 26, 2021	Biogen filed the Delaware action against Teva
2021-2022	Teva litigated infringement and validity defenses
2022	Delaware jury found infringement and rejected Teva’s validity defenses
2022	Jury awarded Biogen approximately $176.5 million
December 2022	District court entered judgment for Teva based on the prior invalidity determination
2023 onward	The case proceeded through post-trial and appellate proceedings concerning issue preclusion and patent validity

The sequence produced a split between the jury verdict and the operative judgment. The jury’s finding favored Biogen, but the district court concluded that the prior Mylan judgment prevented Biogen from relitigating the validity of the same patent.

What did the jury decide in Biogen v. Teva?

The jury found that Teva’s proposed generic dimethyl fumarate product infringed asserted claims of the '514 patent. The jury also found the asserted claims valid and awarded Biogen approximately $176.5 million in damages.

The verdict reflected Biogen’s position that Teva’s proposed ANDA product would practice the patented 480 mg daily treatment regimen. The jury rejected Teva’s arguments that the claims lacked adequate written description and enablement.

The damages award was based on the statutory framework applicable to an ANDA infringement action. Because Teva’s product had not yet entered the market in the ordinary commercial sense, the award was directed to the period associated with the artificial act of infringement and the expected generic launch implications.

Why did the district court enter judgment for Teva?

The district court applied issue preclusion, also known as collateral estoppel, based on the prior Biogen v. Mylan litigation.

In the Mylan case, the Federal Circuit affirmed the determination that the '514 patent was invalid for lack of written description. The court held that the patent specification did not adequately demonstrate possession of the claimed 480 mg daily dose at the relevant filing date.

The Delaware court concluded that the same validity issue had already been litigated and decided. Although Teva was not the defendant in the Mylan action, the court treated the prior invalidity ruling as controlling against Biogen. The result was a judgment for Teva despite the jury’s contrary validity finding.

The decision illustrates a critical patent-litigation principle: a patentee may be unable to obtain a second validity determination after another defendant has successfully invalidated the same patent, particularly when the prior ruling has been affirmed on appeal.

What was the written-description issue?

The written-description dispute concerned whether the '514 specification supported the specific 480 mg daily dose.

Biogen argued that the specification disclosed a broad dosage range and provided sufficient guidance for skilled artisans to identify 480 mg per day as an effective regimen. Teva argued that the patent did not identify that specific dose with adequate clarity and that the claimed regimen was selected from a large number of possible doses without sufficient descriptive support.

The Federal Circuit’s Mylan decision accepted the written-description challenge. The court distinguished between merely describing a broad range that might encompass a claimed dose and demonstrating possession of the particular claimed dose.

That distinction was decisive. The issue was not whether 480 mg per day ultimately worked clinically. It was whether the patent application, as filed, showed that the inventors possessed that specific regimen.

How did Biogen v. Mylan affect the Teva case?

Biogen v. Mylan was the controlling legal event in the Teva litigation.

In Mylan, the Federal Circuit affirmed the invalidity of the '514 patent. The ruling removed the patent’s ability to support a conventional injunction against generic entry if the same invalidity determination applied in later cases.

The Teva court treated the Mylan ruling as preclusive because:

1. The same '514 patent was at issue.
2. The validity issue was the same.
3. The written-description issue had been actually litigated.
4. The prior invalidity ruling was final.
5. The validity determination was essential to the Mylan judgment.

The result was that Biogen could not preserve the jury verdict by obtaining a second finding that the claims were adequately described.

What was the Paragraph IV challenge?

Teva’s ANDA included a Paragraph IV certification asserting that the relevant patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Biogen’s lawsuit was therefore an ANDA litigation action under the Hatch-Waxman Act. Filing the suit triggered the statutory 30-month stay of FDA approval, subject to the statutory and procedural rules governing the ANDA and the listed patent.

Teva’s Paragraph IV position had two components:

• The proposed product did not infringe the asserted claims.
• The asserted claims were invalid, particularly for lack of written description.

The validity challenge ultimately became more important than the infringement dispute because the earlier Mylan ruling undermined the enforceability of the patent claims against later generic applicants.

What was the FDA and Orange Book status?

The '514 patent was listed in the FDA’s Orange Book for Tecfidera-related products and carried a listed expiration date in 2028. The patent listing supported Biogen’s Hatch-Waxman suit against Teva.

The FDA approval status of a generic dimethyl fumarate product is separate from the patent merits. FDA approval addresses safety, efficacy, quality, bioequivalence, labeling, and manufacturing. A court judgment determines whether the applicant may launch without infringing enforceable patent rights.

The invalidity ruling reduced the practical value of the '514 Orange Book listing. Once the patent was held invalid and the judgment became operative, the listed patent no longer provided the same barrier to approval and launch that Biogen had sought to maintain.

Was there FDA exclusivity for Tecfidera?

Tecfidera’s principal protection in the Teva case came from patents rather than an ongoing period of regulatory exclusivity. The product’s 2013 approval date meant that the principal new-drug exclusivity period had expired before the 2021 action.

The commercial dispute therefore focused on patent exclusivity, not an unexpired FDA new chemical entity exclusivity period.

What generic entry risks existed for Tecfidera?

The principal generic-entry risk was early launch following invalidation of the '514 patent.

Tecfidera faced several forms of competition:

• ANDA products containing dimethyl fumarate;
• Authorized or branded-generic versions;
• Alternative fumarate products, including diroximel fumarate;
• Other oral multiple sclerosis therapies;
• Established injectable and infused disease-modifying treatments.

Once the '514 patent could not be enforced against Teva, the remaining barriers depended on other listed patents, regulatory timing, commercial strategy, and manufacturing readiness.

The generic product did not need to copy Biogen’s brand name or commercial presentation. It needed to satisfy the ANDA requirements for the approved dimethyl fumarate product and avoid enforceable patent claims.

How strong was Biogen’s Tecfidera patent estate?

Biogen’s estate had commercial breadth but limited durability for the core dosage patent after the Mylan ruling.

Estate category	Strategic value	Risk profile
Core active ingredient	High if valid, but dimethyl fumarate was not protected by a durable composition patent in this dispute	Vulnerable to generic substitution
480 mg/day dosing regimen	Directly aligned with Tecfidera labeling	Invalidity risk from written-description ruling
Delayed-release formulation	Could create a product-specific barrier	Dependent on claim scope and Orange Book listing
Manufacturing methods	May delay or complicate entry if required by the generic process	Usually narrower and harder to enforce against independent processes
Method-of-use claims	Can reach labeled treatment use	Enforcement may depend on ANDA labeling and induced infringement evidence

The central weakness was the reliance on a single dosing-regimen patent whose validity had already failed in related litigation. The jury verdict showed that infringement evidence could be persuasive, but the final judgment showed that infringement was commercially irrelevant once the patent was held invalid.

Did the case involve formulation patents or method-of-use patents?

The asserted '514 patent was principally a method-of-treatment and dosing-regimen patent. The case did not produce a final determination that all Tecfidera formulation or manufacturing patents were invalid.

Formulation patents can protect:

• Delayed-release delivery;
• Capsule composition;
• Excipients;
• Dissolution profiles;
• Stability characteristics;
• Manufacturing processes.

Method-of-use patents can protect the administration of dimethyl fumarate for multiple sclerosis, including dose, frequency, patient population, or treatment sequence.

The Teva litigation should therefore not be read as eliminating every potential Tecfidera-related patent right. Its direct effect was on the asserted '514 patent and Biogen’s ability to enforce that patent against Teva’s ANDA.

Which companies challenged Tecfidera exclusivity?

The most important challengers included:

• Mylan Pharmaceuticals, which successfully challenged the validity of the '514 patent;
• Teva Pharmaceuticals Development Inc., which litigated infringement and validity in the Delaware case;
• Other generic applicants pursuing ANDAs for dimethyl fumarate;
• Manufacturers of competing fumarate products, including products based on diroximel fumarate.

The Mylan and Teva cases were linked by the same patent and the same written-description dispute. The cases demonstrate why a first-filed or first-decided ANDA challenge can affect later applicants even when the later case has a different defendant and produces a different jury record.

What was the commercial impact on Biogen?

Tecfidera was a major Biogen revenue product before generic erosion. Loss of enforceability of the '514 patent increased the risk of price compression, formulary substitution, and rapid share loss.

The $176.5 million jury award was significant as litigation damages, but the judgment for Teva eliminated that award as the operative case result. The more important economic consequence was the loss of a potential patent-based launch barrier through 2028.

The commercial exposure included:

• Lower net sales from generic substitution;
• Rebates and discounts required to retain formulary position;
• Reduced negotiating leverage with payers;
• Acceleration of product-mix migration toward newer multiple sclerosis therapies;
• Increased importance of Biogen’s alternative fumarate and next-generation products.

What is the current litigation significance of the case?

The case is significant for three reasons.

First, it confirms that a favorable jury verdict may not survive a post-trial validity ruling grounded in an earlier appellate decision.

Second, it shows the risk of dosage patents that claim a commercially important dose without sufficiently specific disclosure in the original specification.

Third, it demonstrates that a patent owner’s Orange Book listing does not ensure durable exclusivity. The listing can support an ANDA lawsuit, but the patent must survive validity challenges and collateral-estoppel arguments.

Key Takeaways

• Biogen sued Teva over an ANDA for generic dimethyl fumarate delayed-release capsules.
• The principal patent was U.S. Patent No. 8,399,514, listed to expire June 1, 2028.
• A Delaware jury found infringement and validity and awarded approximately $176.5 million.
• The district court later entered judgment for Teva based on the prior invalidity ruling in Biogen v. Mylan.
• The controlling weakness was lack of written-description support for the claimed 480 mg/day regimen.
• The case reduced the practical value of Biogen’s core Tecfidera dosage patent.
• The dispute involved patent exclusivity, not an unexpired FDA new-drug exclusivity period.
• Generic entry risk extended beyond Teva to other ANDA applicants and competing fumarate products.
• Formulation and manufacturing patents may remain relevant, but they were not the basis of the principal judgment in this action.

FAQs

What drug was at issue in Biogen v. Teva?

The dispute concerned generic dimethyl fumarate delayed-release capsules, the generic equivalent of Biogen’s Tecfidera for multiple sclerosis.

How much did Biogen win from Teva at trial?

The jury awarded Biogen approximately $176.5 million after finding infringement of the asserted '514 patent claims.

Why did Teva ultimately prevail despite the jury verdict?

The district court applied issue preclusion based on the prior Federal Circuit ruling that invalidated the same '514 patent for lack of written description.

Did the case invalidate all Tecfidera patents?

No. The judgment directly concerned the asserted '514 patent. It did not automatically invalidate every formulation, manufacturing, or method-of-use patent associated with Tecfidera.

What does the case mean for future dosage-regimen patents?

The case shows that a claimed dose must be specifically supported by the patent application as filed. A broad disclosure that encompasses a dose may not satisfy the written-description requirement.

References

1. Biogen Inc. v. Teva Pharmaceuticals Development Inc., No. 1:21-cv-00389, U.S. District Court for the District of Delaware, docket filings and orders.

2. Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18-1165, U.S. Court of Appeals for the Federal Circuit (2020).

3. U.S. Food and Drug Administration. (2013). FDA approves new multiple sclerosis treatment Tecfidera. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Patent No. 8,399,514. (2013). Methods of treating multiple sclerosis. United States Patent and Trademark Office.